Revolutionizing Atopic Dermatitis

In this interview, Yosipovitch touches on the topics featured in his RAD 2025 presentation ‘Managing Itch,’ specifically regarding patients with atopic dermatitis.

This interview with Peter Lio, MD, at RAD 2025 provides several insights into the topic of topical steroid withdrawal versus atopic dermatitis and what the distinction may be.

In this interview at RAD 2025, Peter Lio, MD, highlighted whether precision medicine is a possibility in the near future in the atopic dermatitis management space.

In this Q&A discussion, Glick highlights several important points about topical steroid withdrawal and atopic dermatitis.

This study highlights rates among females with up to 6 years of upadacitinib use of major adverse cardiovascular events, VTE, and malignancy.

This Q&A interview features Jeff Yu, MD, in a discussion regarding his presentation on chronic hand eczema at the 2025 RAD Conference.

These late-breaking data highlight the real-world efficacy of upadacitinib for patients with atopic dermatitis who are either bio-naïve or bio-experienced.

This interview at RAD 2025 highlights several notes on dose flexibility in atopic dermatitis, with commentary by presenter Raj Chovatiya, MD, PhD.

These late-breaking data presented at RAD 2025 highlight dupilumab’s efficacy and safety in this often neglected patient population.

These phase 3b findings highlight lebrikizumab’s efficacy and safety in adult and adolescent patients with skin of color living with atopic dermatitis.

This interview features a discussion with Lio regarding pediatric atopic dermatitis and the connection between caregivers, patients, and providers.

This interview with Singh highlights her conference presentation on allergy and its connection to pediatric atopic dermatitis.

This interview highlights 3 new topical non-steroidal options for atopic dermatitis covered in Kircik’s RAD 2025 presentation on FDA approvals.

In this interview with Shahriari at RAD 2025, she highlights some of the most significant burdens that patients and caregivers face with atopic dermatitis.

In this Q&A interview, Silverberg highlighted takeaways from his talk at RAD 2025 on recent FDA approvals for atopic dermatitis.

In this session at RAD 2025, Tiffany Mayo, MD, spoke to attendees about several examples of complex cases in atopic dermatitis and touched on hair loss concerns.

In this video segment, Kircik described the data highlighted in his JAK inhibitor-related presentation at RAD 2025.

This interview highlights the takeaways from Kircik’s talk at the 2025 RAD Conference regarding JAK inhibitor use and boxed warning concerns.

This summary features a variety of abstracts to be presented at the RAD meeting in June 2025, highlighting new data in atopic dermatitis and the dermatology space in general.

Mona Shahriari, MD, previews the upcoming Revolutionizing Atopic Dermatitis Annual Meeting being held in Nashville, TN from June 06-07.

Brett King, MD, PhD, discusses the LEVEL UP trial and how it represents the field of dermatology's desire to advance care and advocate for new standards of care.

These data, presented at RAD 2024, highlight the potential of delgocitinib cream for patients with chronic hand eczema in terms of patient and clinician reported outcomes.

These data highlighted which drug, in combination with topical corticosteroids, produced the best efficacy results for those with atopic dermatitis.

These data, presented at RAD 2024, highlight the potential benefits of upadacitinib for adults and adolescents observed in the Measure Up 1 and Measure Up 2 studies.

Sidbury covered the similarities and differences between the new guideline updates by the AAD on atopic dermatitis as well as differences with other organizations’ guidelines.

In new late-breaking data, alopecia patients’ real-world incidence of atopic dermatitis was highlighted by investigators.

These data presented at RAD 2024 highlight the differences among eczema patient preferences in terms of administration modes, risk levels, and more.

An analysis of survey data from more than 200 patients with atopic dermatitis details treatment satisfaction and provider trust based on racial/ethnic backgrounds of patients.

This late-breaking data featured at RAD 2024 highlights several improvements in patient reported outcomes observed among atopic dermatitis patients, including itch relief.

This interview at RAD 2024 featured a discussion by Bissonnette of recent data related to 4 topical drugs for patients with atopic dermatitis.